Bokus

Steven J. Shire – författare

Visar alla böcker från författaren Steven J. Shire. Handla med fri frakt och snabb leverans.

3 produkter

  1. S. Shire, Steven J. Shire, Wayne Gombotz, Karoline Bechtold-Peters, James Andya - Current Trends in Monoclonal Antibody Development and Manufacturing, Inbunden. Tillgänglighet: Lägg i varukorg

    Current Trends in Monoclonal Antibody Development and Manufacturing

    Av S. Shire, Steven J. Shire m. fl.

    Inbunden, 2009

    2247 kr

    Lägg i varukorg

    Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are …

  2. James Andya, Karoline Bechtold-Peters, Wayne Gombotz, Steven J. Shire - Current Trends in Monoclonal Antibody Development and Manufacturing, E-bok. Tillgänglighet: Lägg i varukorg

    Current Trends in Monoclonal Antibody Development and Manufacturing

    Av James Andya, Karoline Bechtold-Peters m. fl.

    E-bok, 2009

    3013 kr

    Lägg i varukorg

    Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are …

  3. Steven J. Shire, Wayne Gombotz, Karoline Bechtold-Peters, James Andya - Current Trends in Monoclonal Antibody Development and Manufacturing, Häftad. Tillgänglighet: Lägg i varukorg

    Current Trends in Monoclonal Antibody Development and Manufacturing

    Av Steven J. Shire, Wayne Gombotz m. fl.

    Häftad, 2012

    2312 kr

    Lägg i varukorg

    Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are …